HOME › DRUGS › CANAKINUMAB
ACTIVE SUBSTANCE / INN

CANAKINUMAB

Brand name(s): ILARIS, Canakinumab Novartis, Ilaris
FDA LISTED
EMA LISTED
PRESCRIPTION
APPLICATION WITHDRAWN
AUTHORISED
Acute Coronary Syndrome;Myocardial Infarction;Stroke
BLA125319
ACTIVE SUBSTANCE
Canakinumab
REGULATORS
FDA · EMA
SPONSORS / MAH
NOVARTIS PHARMS, Novartis Europharm Limited
TOTAL APPLICATIONS
3
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
ILARISBLA125319NOVARTIS PHARMSPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
IlarisNovartis Europharm LimitedAuthorised23/10/2009Cryopyrin-Associated Periodic Syndromes;Arthritis, Juvenile Rheumatoid;Arthritis…
Canakinumab NovartisNovartis Europharm LimitedApplication withdrawnAcute Coronary Syndrome;Myocardial Infarction;Stroke

FULL INTELLIGENCE ON CANAKINUMAB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →